Antigen‐Enriched Tumor‐Dendritic Cell Fusion Membrane‐Coated Metal‐Phenolic Nanovaccine Enables Dual T‐Cell Activation for Robust Cancer Immunotherapy
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.202505255 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Lishang Xu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan Province, P. R. China. Hauptthemen laut MEDLINE: Dendritic Cells, Immunotherapy, Cancer Vaccines, Lymphocyte Activation. Die Arbeit nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hunan Provincial Natural Science Foundation for Distinguished Young Scholars, Hunan Provincial Natural Science Foundation.
Abstract (Originalsprache)
Antigen‐enriched tumor vaccines represent a promising strategy for cancer immunotherapy. Nevertheless, their clinical efficacy is often limited by insufficient antigen presentation and low immunogenicity. Here, a novel nanovaccine was developed that synergistically combines mitochondrial fission inhibition, tumor‐dendritic cell fusion, and metal‐phenolic nanoparticle technology. Tumor cells were pretreated with the mitochondrial fission inhibitor Mdivi‑1, yielding antigen‑enriched cell membranes (CM(M)). Subsequently, these CM(M) were fused with the dendritic cell membranes (DCM) overexpressing B7 biomolecules to create a tumor‐dendritic cell fusion membrane (DCCM(M)). R848‐loaded metal‐phenolic nanoparticles (TF/R848) were further coated with the fusion membrane to create a dual‐functional nanovaccine (TF/R848@DCCM(M)). This nanovaccine increases immunogenicity and optimizes antigen presentation. The nanovaccine promotes dual T‐cell activation via direct antigen presentation and DC‐mediated cross‐presentation. TF/R848@DCCM(M) showed remarkable anticancer activity in melanoma‐bearing mouse models, greatly reducing tumor development and extending longevity. Moreover, the nanovaccine enhanced the effects of immune checkpoint inhibitors, offering a promising strategy for combination immunotherapy. This study presents a novel, efficient platform for cancer immunotherapy, positioning a versatile and powerful approach for next‐generation tumor vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan Province, P. R. China.
- Department of Pharmaceutical Engineering, College of Chemistry and Chemical Engineering, Central South University, Changsha, Hunan Province, P. R. China.
- Molecular Imaging Research Center of Central South University, Changsha, Hunan Province, P. R. China.
ORCID-Profile: Zhenbao Liu
Förderung
- National Natural Science Foundation of China
- Hunan Provincial Natural Science Foundation for Distinguished Young Scholars
- Hunan Provincial Natural Science Foundation
- Innovation-Driven Project of Central South University
- Hunan Provincial High-Level Health Talents
- Joint Fund of the Hunan Provincial Natural Science Foundation and the Hunan Medical Products Administration
- Postgraduate Innovation Project of Central South University
Zitieren
APA
Xu, L., Shao, K., Liu, Y., Liu, Y., Tan, Y., Man, Y., Zhang, Z., Cheng, Z., Wang, Q., Ren, Z., Wu, J., Chen, Q. W., & Liu, Z. (2026). Antigen‐Enriched Tumor‐Dendritic Cell Fusion Membrane‐Coated Metal‐Phenolic Nanovaccine Enables Dual T‐Cell Activation for Robust Cancer Immunotherapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202505255
Vancouver
Xu L, Shao K, Liu Y, Liu Y, Tan Y, Man Y, et al. Antigen‐Enriched Tumor‐Dendritic Cell Fusion Membrane‐Coated Metal‐Phenolic Nanovaccine Enables Dual T‐Cell Activation for Robust Cancer Immunotherapy. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202505255
BibTeX
@article{Xu2026,
author = {Xu, Lishang and Shao, Kan and Liu, Yanfei and Liu, Yongbo and Tan, Yifu and Man, Yunqi and Zhang, Zhirou and Cheng, Zhongyu and Wang, Qian and Ren, Zhihang and Wu, Jian and Chen, Qi-Wen and Liu, Zhenbao},
title = {Antigen‐Enriched Tumor‐Dendritic Cell Fusion Membrane‐Coated Metal‐Phenolic Nanovaccine Enables Dual T‐Cell Activation for Robust Cancer Immunotherapy},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.202505255}
}
EUVIMED